Brentuximab vedotin
- PDF / 169,214 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 95 Downloads / 156 Views
1
S
Peripheral neuropathy following off-label use: case report In a prospective analysis of 27 patients, who commenced brentuximab vedotin between February 2015 and April 2019, a patient [age and sex not stated] was described, who developed grade 3 peripheral neuropathy during off-label treatment with brentuximab vedotin [route, dosage, indication, duration of treatment to reaction onset and outcome not stated]. Author comment: "We noted a high rate of admission for toxicity following cycle 1." "17 patients developed peripheral neuropathy (G1 = 11, G2 = 5, G3 = 1)." "Brentuximab vedotin (BV) was available via a compassionate use program". Enefer S, et al. Treatment of mycosis fungoides/Sezary syndrome with brentuximab vedotin on the compassionate use program and CDF: outcomes and toxicities. European Journal of Cancer 119 (Suppl. 1): S29 abstr. 079, Sep 2019. Available from: URL: http://doi.org/10.1016/S0959-8049%2819%2930589-1 803435503 [abstract] - United Kingdom
0114-9954/19/1780-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 23 Nov 2019 No. 1780
Data Loading...
